ALGS Valuation

Aligos Therapeutics Inc

Add to Watchlist

Advanced Chart

10.200

+0.36(3.659%)1D

Overview
Forecast
Valuation
Earnings

ALGS Relative Valuation

ALGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALGS is overvalued; if below, it's undervalued.

Historical Valuation

Aligos Therapeutics Inc (ALGS) is now in the Fair zone, suggesting that its current forward PS ratio of 54.44 is considered Fairly compared with the five-year average of -3.24. The fair price of Aligos Therapeutics Inc (ALGS) is between 2.95 to 11.14 according to relative valuation methord.

Relative Value

Fair Zone

2.95-11.14

Current Price：10.20

Fair

-1.16

Trailing

Forward

0.00

EV/EBITDA

Aligos Therapeutics Inc. (ALGS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -4.38. The thresholds are as follows: Strongly Undervalued below -20.07, Undervalued between -20.07 and -12.22, Fairly Valued between 3.47 and -12.22, Overvalued between 3.47 and 11.31, and Strongly Overvalued above 11.31. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.64

EV/EBIT

Aligos Therapeutics Inc. (ALGS) has a current EV/EBIT of 0.64. The 5-year average EV/EBIT is -4.37. The thresholds are as follows: Strongly Undervalued below -20.03, Undervalued between -20.03 and -12.20, Fairly Valued between 3.47 and -12.20, Overvalued between 3.47 and 11.30, and Strongly Overvalued above 11.30. The current Forward EV/EBIT of 0.64 falls within the Historic Trend Line -Fairly Valued range.

54.44

Aligos Therapeutics Inc. (ALGS) has a current PS of 54.44. The 5-year average PS is 64.03. The thresholds are as follows: Strongly Undervalued below -261.98, Undervalued between -261.98 and -98.98, Fairly Valued between 227.03 and -98.98, Overvalued between 227.03 and 390.03, and Strongly Overvalued above 390.03. The current Forward PS of 54.44 falls within the Historic Trend Line -Fairly Valued range.

-0.63

P/OCF

Aligos Therapeutics Inc. (ALGS) has a current P/OCF of -0.63. The 5-year average P/OCF is -5.87. The thresholds are as follows: Strongly Undervalued below -23.90, Undervalued between -23.90 and -14.88, Fairly Valued between 3.14 and -14.88, Overvalued between 3.14 and 12.16, and Strongly Overvalued above 12.16. The current Forward P/OCF of -0.63 falls within the Historic Trend Line -Fairly Valued range.

-0.65

P/FCF

Aligos Therapeutics Inc. (ALGS) has a current P/FCF of -0.65. The 5-year average P/FCF is -6.48. The thresholds are as follows: Strongly Undervalued below -28.53, Undervalued between -28.53 and -17.50, Fairly Valued between 4.55 and -17.50, Overvalued between 4.55 and 15.58, and Strongly Overvalued above 15.58. The current Forward P/FCF of -0.65 falls within the Historic Trend Line -Fairly Valued range.

Aligos Therapeutics Inc (ALGS) has a current Price-to-Book (P/B) ratio of 0.59. Compared to its 3-year average P/B ratio of 1.17 , the current P/B ratio is approximately -49.34% higher. Relative to its 5-year average P/B ratio of 2.21, the current P/B ratio is about -73.16% higher. Aligos Therapeutics Inc (ALGS) has a Forward Free Cash Flow (FCF) yield of approximately -137.99%. Compared to its 3-year average FCF yield of -98.64%, the current FCF yield is approximately 39.90% lower. Relative to its 5-year average FCF yield of -69.12% , the current FCF yield is about 99.63% lower.

0.59

P/B

Median3y

1.17

Median5y

2.21

-137.99

FCF Yield

Median3y

-98.64

Median5y

-69.12

Competitors Valuation Multiple

The average P/S ratio for ALGS's competitors is 9.07, providing a benchmark for relative valuation. Aligos Therapeutics Inc Corp (ALGS) exhibits a P/S ratio of 54.44, which is 500.00% above the industry average. Given its robust revenue growth of -9.05%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ALGS.O

Aligos Therapeutics Inc

Cumberland Pharmaceuticals Inc

Tempest Therapeutics Inc

Loss

44.51M

TELO.O

Telomir Pharmaceuticals Inc

Performance Decomposition

Market capitalization of ALGS decreased by 19.56% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.19 to -1.04.

The secondary factor is the Revenue Growth, contributed -9.05%to the performance.

Overall, the performance of ALGS in the past 1 year is driven by P/E Change. Which is more unsustainable.

-9.05%

1.06M → 965.00K

Revenue Growth

-444.62%

477.00 → -1.64K

Margin Expansion

434.11%

-0.19 → -1.04

P/E Change

-19.56%